Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$2.00M-$2.00MN/M vs Q3 2021 EPS, diluted—
Operating Income-$2,000,094N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,488,213N/M ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end